Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 95-100 , 15 April 2010

Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis

  • Makoto Hirotani

      Affiliations

    • Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    • ,
  • Masaaki Niino

      Affiliations

    • Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    • Corresponding Author InformationCorresponding author. Department of Neurology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638 Japan. Tel.: +81 11 706 6028; fax: +81 11 700 5356.
    • ,
  • Toshiyuki Fukazawa

      Affiliations

    • Sapporo Neurology Clinic, Sapporo, Japan
    • ,
  • Seiji Kikuchi

      Affiliations

    • Department of Neurology, Sapporo Minami National Hospital, Sapporo, Japan
    • ,
  • Ichiro Yabe

      Affiliations

    • Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    • ,
  • Shinsuke Hamada

      Affiliations

    • Hokuyukai Neurological Hospital, Sapporo, Japan
    • ,
  • Yasutaka Tajima

      Affiliations

    • Department of Neurology, Sapporo City General Hospital, Sapporo, Japan
    • ,
  • Hidenao Sasaki

      Affiliations

    • Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Received 20 October 2009 ,Revised 26 January 2010 ,Accepted 12 February 2010.

References 

  1. Bach JF. The effect of infections on susceptibility to autoimmune encephalomyelitis. N. Engl. J. Med. 2002;347:911–920
  2. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. Blood. 2003;101:4500–4504
  3. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 2006;177:7551–7558
  4. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007;178:6092–6099
  5. Fillatreau S, Sweenie C, McGeacht MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002;3:944–950
  6. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune response. Nat. Immunol. 2004;5:987–995
  7. Lampropoulou V, Hoehlig K, Roch T, Neves P, Gomez EC, Sweenie CH, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 2008;180:1763–1773
  8. Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease: I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun. 2002;5:675–690
  9. Marta M, Andersson A, Isaksson M, Kampe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008;38:565–575
  10. McGeachy MJ, Bak-Jansen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007;8:1390–1397
  11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  12. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006;203:456–464
  13. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferonβ-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504
  14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003;21:424–432
  15. The IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661
  16. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 2000;176:154–170
  17. Wolf SD, Dittel BN, Hardardottir F, Janeway CA. Experimental autoimmune encephalomyelitis induction in B cell-deficient mice. J. Exp. Med. 1996;184:2271–2278
  18. Zhang X, Tang Y, Sujkowska D, Wang D, Ramgolam V, Sospedra M, et al. Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur. J. Immunol. 2008;38:1297–1309
  19. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFNβ-1a inhibits the secretion of TH17-polarizing cytokines in human dendritic cells via TLR8 up-regulation. J. Immunol. 2009;182:3928–3936

PII: S0165-5728(10)00061-5

doi: 10.1016/j.jneuroim.2010.02.012

Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 95-100 , 15 April 2010

Article Tools

* Image Usage & Resolution